Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
HOME > ACADEMIA
ACADEMIA
- Japan Hypertension Society Announces COI Guide after Diovan Woes
October 5, 2015
- JSNP Finalizes Evidence-Based Guidelines for Treatment of Schizophrenia
September 28, 2015
- Experts, Industry Execs Say Cost Calculation Drug Pricing Method Fraught with Challenges
September 8, 2015
- ASCO Immunotherapy Roundup - 9: Researcher Says Predominance of Anti-PD-1 Antibodies Not Assured
September 1, 2015
- Japan’s National Database “World’s Largest in Scale”: Kyoto University Prof. Nakayama
August 20, 2015
- Genome Sequencing Study of Biliary Tract Cancer Suggests Effectiveness of Immune Checkpoint Therapy: National Cancer Center
August 12, 2015
- St. Marianna Univ. Hospital Introduces Tougher Rules for Adopting New Drugs with Emphasis on Cost, Efficacy, and Safety
July 28, 2015
- PD-L1 Expression Key to Decide Whether to Combine Opdivo, Yervoy: Oncologist
July 21, 2015
- Japan, US Oncologists Exchange Barbs over Opdivo Costs
July 21, 2015
- Japan Lung Cancer Society Petitions Health Minister for Early Approval of AZ’s AZD9291 for EGFR-TKI-Resistant NSCLC
July 8, 2015
- NCC Starts PI Study of Nucleic Acid Drug in Treatment-Resistant Locally Advanced or Recurrent Breast Cancer
July 8, 2015
- JSGM to Issue Policy Proposal after MHLW Sets New Target for Generic Market Share
June 17, 2015
- AGs “Will Energize the Generic Drug Market”: Prof. Sakamaki
June 17, 2015
- MHLW Official Urges Generic Drug Makers to Expand into Overseas Markets
June 17, 2015
- MHLW Official Restates Difficulty of Moving Up Timeline to Attain 80% Generic Share
June 16, 2015
- Tiotropium Positioned in Step 3 and Step 4 Care for Asthma: Japanese Society of Allergology’s Revised Guidelines
June 5, 2015
- Pfizer Poised to Emerge as Global Leader in Oncology: Chief Medical Officer
June 3, 2015
- Xtandi Monotherapy Meets Primary Endpoint in PII Study for Triple-Negative Breast Cancer: Astellas
June 3, 2015
- 3 of 20 Japanese Gastric Cancer Patients Show PR to PD-L1 Inhibitor Avelumab: ASCO
June 3, 2015
- Ibrance Prolongs PFS in Second-Line for Advanced Breast Cancer: ASCO
June 3, 2015
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…